CLL/SLL Patients: Real-World Outcomes with First-Line Ibrutinib (Ibr) VS. Chemoimmunotherapy (CIT)
With the development of cutting-edge drugs like Ibr, the treatment landscape for CLL/SLL has...
Read More
Dissemination (Meeting Coverage)
African American Patients with Diffuse Large B-Cell Lymphoma: Predictors of Inferior Survival
African American (AA) patients with diffuse large b-cell lymphoma (DLBCL) experience differences...
Read More
Neutrophil-to-Lymphocyte Ratio in Gout Suggests Sustained Post-Flare Inflammation
At the 2022 American College of Rheumatology Convergence meeting, Michael Pillinger, MD, presented...
Read More
Patients With IBS With Diarrhea Experience Significant Burden on HRQOL
For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such as abdominal pain...
Read MoreDiffuse Large B-Cell Lymphoma Patients: Impact of Circulating Lymphoma at Diagnosis on Outcomes
The most prevalent B-cell non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). Various prognostic factors were known, including the revised international prognostic index (R-IPI), MYC/BCL2 overexpression by IHC,...
Read MorePatients With IBS With Diarrhea Experience Significant Burden on HRQOL
Patients with IBS-D had significantly higher percentages of moderate to severe anxiety and depression and considerably lower HRQOL versus controls. For patients with irritable bowel syndrome with diarrhea (IBS-D), symptoms such...
Read More
Predictor of Response to Loncastuximab Tesirine: Expression by IHC
A number of CD19-targeted medicines, such as chimeric antigen receptor T-cell therapy (CAR-T),...
Read More
Relapsed/Refractory DLBCL Patients Treated with Loncastuximab Tesirine: Predicting Outcome by Metabolic Tumor Volume
For tailored therapy selection and result optimization in diffuse large B-cell lymphoma (DLBCL),...
Read More
MIRROR RCT Trial: Addressing Gout Following Kidney Transplant
Results from the MIRROR RCT trial, presented at the 2022 American Society of Nephrology’s Kidney...
Read More
Patients With Comorbid Gout Hospitalized With COVID-19 Have Greater LOS
Gout flares occurred in 18% of patients with comorbid gout who were hospitalized for COVID-19,...
Read More
IgG-Based Diets Can Provide Relief for Some Patients With IBS
IgG-based elimination diets using a novel diagnostic tool to guide therapy may be beneficial to...
Read More
ULT for Gout Leads to Long-Term Reduction in Hospitalization Risk After Initial Spike
For patients with gout, urate-lowering therapy (ULT) increases the risk of hospitalizations within...
Read More
Baseline Cholesterol Biomarkers Impact CV Risk in Elderly Patients
Individuals with hypercholesterolemia who had higher levels of campesterol experienced...
Read More
Returning Secondary Findings Related to Hypercholesterolemia Has Clinical Benefits
Limited research has been done on outcomes after the return of secondary findings in large-scale...
Read More
PCSK9 Monoclonal Antibody Provides ‘Significant and Durable’ Decrease in LDL-C
Tafolecimab provided significant, durable decreases in low-density lipoprotein cholesterol (LDL-C)...
Read More
VICTORION-INCEPTION: Inclisiran Immediately After ACS for Secondary Prevention
VICTORION-INCEPTION is a phase IIIb, randomized, parallel-group, open-label, multicenter, US-based...
Read More
ORION-3: Long-Term Inclisiran Safe & Feasible
The principal finding from a 4-year open-label extension study of inclisiran—a small interfering...
Read More
For Refractory/Relapsed AML, Total Therapy Proves Superior to Standard Care
For patients with refractory/relapsed acute myeloid leukemia (AML), total therapy, as compared...
Read More
Gout More Prevalent in Black Adults Than in Whites, Especially Black Women
Compared with their White counterparts, gout is more prevalent in Black adults, according to the...
Read More
Link Found Between Gout Flare and Subsequent Cardiovascular Events
Compared with patients with gout who did not experience a cardiovascular (CV) event, those who did...
Read More